Showing 701 - 720 results of 2,809 for search 'Khaas~', query time: 3.45s Refine Results
  1. 701
  2. 702
  3. 703

    Hypertension-Related Gene Polymorphisms of G-Protein-Coupled Receptor Kinase 4 Are Associated with NT-proBNP Concentration in Normotensive Healthy Adults by Junichi Yatabe, Midori S. Yatabe, Minoru Yoneda, Robin A. Felder, Pedro A. Jose, Hironobu Sanada

    Published 2012-01-01
    “…G protein-coupled receptor kinase 4 (GRK4) with activating polymorphisms desensitize the natriuric renal tubular D1 dopamine receptor, and these GRK4 polymorphisms are strongly associated with salt sensitivity and hypertension. …”
    Get full text
    Article
  4. 704
  5. 705

    The Effects of Anlotinib Combined with Chemotherapy following Progression on Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor-Positive Metastatic Breast Cancer by Ting Xu, Weili Xiong, Lili Zhang, Yuan Yuan

    Published 2024-01-01
    “…Endocrine therapy combined with cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6i) is the preferred treatment for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer (MBC). …”
    Get full text
    Article
  6. 706
  7. 707

    Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase II (CaMKII) Regulates Basal Cardiac Pacemaker Function: Pros and Cons by Tatiana M. Vinogradova, Edward G. Lakatta

    Published 2024-12-01
    Subjects: “…Ca<sup>2+</sup>/calmodulin-dependent protein kinase II (CaMKII)…”
    Get full text
    Article
  8. 708
  9. 709

    Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid Leukemia by Melea A. Ward, Gang Fang, Kristy L. Richards, Christine M. Walko, Stephanie R. Earnshaw, Laura E. Happe, Susan J. Blalock

    Published 2015-04-01
    “…**Background:** Research has shown that treatment interruptions are associated with worse failure-free survival in chronic myeloid leukemia (CML); however they are commonly used in clinical trials to manage adverse events. …”
    Get full text
    Article
  10. 710
  11. 711
  12. 712
  13. 713
  14. 714
  15. 715
  16. 716
  17. 717
  18. 718

    Hereditary Xerocytosis due to Mutations in PIEZO1 Gene Associated with Heterozygous Pyruvate Kinase Deficiency and Beta-Thalassemia Trait in Two Unrelated Families by Elisa Fermo, Cristina Vercellati, Anna Paola Marcello, Anna Zaninoni, Richard van Wijk, Nadia Mirra, Cristina Curcio, Agostino Cortelezzi, Alberto Zanella, Wilma Barcellini, Paola Bianchi

    Published 2017-01-01
    “…The concomitant defects did not aggravate the clinical phenotype; however, in one patient, the initial diagnosis of pyruvate kinase deficiency delayed the correct diagnosis of HX for many years and resulted in splenectomy followed by thrombotic complications. …”
    Get full text
    Article
  19. 719

    Separable roles of the DNA damage response kinase Mec1ATR and its activator Rad24RAD17 during meiotic recombination. by Margaret R Crawford, Jon A Harper, Tim J Cooper, Marie-Claude Marsolier-Kergoat, Bertrand Llorente, Matthew J Neale

    Published 2024-12-01
    “…During meiosis, programmed DNA double-strand breaks (DSBs) are formed by the topoisomerase-like enzyme, Spo11, activating the DNA damage response (DDR) kinase Mec1ATR via the checkpoint clamp loader, Rad24RAD17. …”
    Get full text
    Article
  20. 720